Q-omics provides the consensus-scored BTNL3 profile across patient tissues and cancer cell-line models. BTNL3 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, BTNL3 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, BTNL3 RNA expression shows 10,701 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight MESO, COAD, and ESCA as cancer lineages where BTNL3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BTNL3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BTNL3 survival associations across molecular data types. BTNL3 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BTNL3 RNA expression–survival associations across cancer types. High BTNL3 expression shows unfavorable associations in STAD, SCLC, TGCT and ESCA, but favorable associations in MESO and READ. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for BTNL3 RNA expression.
This table summarizes BTNL3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for BTNL3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BTNL3 shows lower tumor expression in COAD, LUAD, BRCA, READ and LUSC and higher tumor expression in KIRC. The COAD box plot shows higher BTNL3 RNA expression in normal versus tumor tissue (log2 FC = −3.363, t-test p < 0.001).
This table shows molecular features associated with BTNL3 in patient tissues and cancer cell lines. In patient samples, BTNL3 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, BTNL3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
